4295-05-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-chloro-2-Methoxyquinoline is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, due to its unique chemical structure and potential biological activities.
Used in Antitumor Applications:
4-chloro-2-Methoxyquinoline is used as a potential antitumor agent, as it has been studied for its ability to inhibit tumor growth and progression, making it a promising candidate for cancer treatment.
Used in Antimalarial Applications:
4-chloro-2-Methoxyquinoline is used as a potential antimalarial agent, as it has been studied for its ability to inhibit the growth of Plasmodium parasites, which cause malaria.
Used in Enzyme Inhibition:
4-chloro-2-Methoxyquinoline is used as an inhibitor of certain enzymes, which can be beneficial in the development of drugs targeting specific enzyme-related diseases.
Used in Fluorescent Probe Development for Biological Imaging:
4-chloro-2-Methoxyquinoline is used in the development of fluorescent probes for biological imaging, due to its fluorescent properties, which can aid in visualizing cellular processes and structures.
Used in Organic Synthesis:
4-chloro-2-Methoxyquinoline is used as a versatile compound in organic synthesis, enabling the creation of various chemical compounds with potential applications in different fields.

Upstream product

• 124-41-4 sodium methylate 
• 703-61-7 2,4-dichloroquinoline 
• 67-56-1 methanol 

Relevant academic research and scientific papers

Diaryl-substituted 1, 1-ethylene compounds and preparation method and application thereof

The invention discloses diaryl-substituted 1, 1-ethylene compounds shown as general formulas I, II, III and IV, and a preparation method and application thereof, and the compounds can be used for preparing medicines related to tumor treatment, tubulin activity inhibition and HDAC activity inhibition.

Quinoline substituted indole compound, and preparation method and application thereof

The invention discloses a quinoline substituted indole compound, a pharmaceutical composition containing the quinoline substituted indole compound, and a preparation method for the quinoline substituted indole compound. The invention also discloses the quinoline substituted indole compound, a pharmaceutical application for the pharmaceutical composition containing the quinoline substituted indolecompound, specifically an application of the pharmaceutical composition containing the quinoline substituted indole compound in preparation of drugs used for treatment of tumors, and an application ofthe quinoline substituted indole compound in preparation of drugs used for treatment of diseases or symptoms by inhibition of tubulin activity.

4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity

4-Aminoquinolone piperidine amides (AQs) were identified as a novel scaffold starting from a whole cell screen, with potent cidality on Mycobacterium tuberculosis (Mtb). Evaluation of the minimum inhibitory concentrations, followed by whole genome sequencing of mutants raised against AQs, identified decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) as the primary target responsible for the antitubercular activity. Mass spectrometry and enzyme kinetic studies indicated that AQs are noncovalent, reversible inhibitors of DprE1 with slow on rates and long residence times of ～100 min on the enzyme. In general, AQs have excellent leadlike properties and good in vitro secondary pharmacology profile. Although the scaffold started off as a single active compound with moderate potency from the whole cell screen, structure-activity relationship optimization of the scaffold led to compounds with potent DprE1 inhibition (IC50 10 nM) along with potent cellular activity (MIC = 60 nM) against Mtb.

Euodenine A: A small-molecule agonist of human TLR4

A small-molecule natural product, euodenine A (1), was identified as an agonist of the human TLR4 receptor. Euodenine A was isolated from the leaves of Euodia asteridula (Rutaceae) found in Papua New Guinea and has an unusual U-shaped structure. It was synthesized along with a series of analogues that exhibit potent and selective agonism of the TLR4 receptor. SAR development around the cyclobutane ring resulted in a 10-fold increase in potency. The natural product demonstrated an extracellular site of action, which requires the extracellular domain of TLR4 to stimulate a NF-κB reporter response. 1 is a human-selective agonist that is CD14-independent, and it requires both TLR4 and MD-2 for full efficacy. Testing for immunomodulation in PBMC cells shows the induction of the cytokines IL-8, IL-10, TNF-α, and IL-12p40 as well as suppression of IL-5 from activated PBMCs, indicating that compounds like 1 could modulate the Th2 immune response without causing lung damage.

N-HETEROARYL COMPOUNDS

This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to novel N-heteroaryl compounds and the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

Demethylation of 2,4-dimethoxyquinolines: the synthesis of atanine.

The synthesis of the quinoline alkaloid atanine 6, by selective demethylation of the 2,4-dimethoxyquinoline 11 is presented. An alternative demethylation utilising a thiolate anion leads to the regioisomeric 4-hydroxyquinoline 13.

Further studies of regioselective alkoxydehalogenation of 2,4-dichloroquinolines, 2,6-dichloropyridine and 2,4-dichloronitrobenzene

Regioselective alkoxydehalogenation reactions using solid alkoxide in toluene have been studied. 2-Alkoxy-4-haloquinolines were obtained from 2,4-dichloroquinolines. With 2,6-dichloropyridine, α-regioselectivity occurred to furnish the 2-alkoxy-6-chloropyridine. The reaction failed with 2,4-dichloronitrobenzene indicating that alkoxide surface contact with a basic heterocyclic nitrogen lone pair was essential for success. Comparative studies with the standard alkoxydehalogenation reaction (alcoholic alkoxide solution) have been performed, all compounds have been identified by 1H and 13C NMR.

Regioselective Alkoxydehalogenation of 2,4-Dihalogenoquinolines and a Reinvestigation of the Bromination of 2-Methoxyquinoline

Regioselective alkoxydehalogenation of 2,4-dichloro- and 2,4-dibromo-quinoline with solid sodium alkoxide in toluene gives the 2-alkoxy-4-halogenoquinolines 7-10, identified by 1H and 13C NMR spectroscopy.Bromination of 2-methoxyquinoline occurs at the 6- and 8-positions and does not give the 4-bromo derivative as originally reported.